Farrugia, Albert; O'Mahony, B; Cassar, J
Although the funding of rare diseases such as haemophilia in developing countries remains a low priority, pressures on the funding of haemophilia treatment are also emerging in developed economies affected by the global economic downturn and the other demands on health care budgets. This is leading advisory bodies and payers alike to explore the tools of Health Technology Assessment (HTAs) in deriving recommendations for reimbursement policies. In particular, the use of cost utility analysis...[Show more]
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.